Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldschmidt

Showing results (351-360 of 472) with videos related to

Pageof 48
Sort By:
Journal of the American Veterinary Medical Association|September 7, 1999
Eosinophilic dermatitis with edema in nine dogs, compared with eosinophilic cellulitis in humansK S Holm, D O Morris, S M Gomez, et al.
Veterinary Dermatology|December 9, 2004
A retrospective study comparing the histopathological features and response to treatment in two canine nasal dermatoses, DLE and MCPS P Wiemelt, M H Goldschmidt, J S Greek, et al.
The Cochrane Database of Systematic Reviews|July 26, 2002
Bisphosphonates in multiple myelomaB Djulbegovic, K Wheatley, J Ross, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 11, 2001
Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasoneG Egerer, U Hegenbart, H Salwender, et al.
Veterinary Dermatology|September 6, 2019
Discriminatory features of acute eosinophilic dermatitis with oedema (Wells-like syndrome) and sterile neutrophilic dermatosis (Sweet's-like syndrome) in dogsCharles W Bradley, Christine L Cain, Talia S Wong, et al.
Therapeutic Advances in Medical Oncology|June 26, 2023
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)Ran Jin, Adesuwa S Ogbomo, Neil A Accortt, et al.
Bone Marrow Transplantation|November 18, 2000
Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myelomaF W Cremer, E Ehrbrecht, K Kiel, et al.
Bone Marrow Transplantation|December 1, 1993
Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphomaR Haas, R Ehrhardt, B Witt, et al.
Leukemia|September 17, 2010
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activationA C Sprynski, D Hose, A Kassambara, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 1, 1995
[Sequential high-dose therapy in patients with low-malignity non-Hodgkin's lymphoma]R Haas, M Moos, A Karcher, et al.
Pageof 48

Showing results (351-360 of 472) with videos related to

Sort By:
Pageof 48
Journal of the American Veterinary Medical Association|September 7, 1999
Eosinophilic dermatitis with edema in nine dogs, compared with eosinophilic cellulitis in humansK S Holm, D O Morris, S M Gomez, et al.
Veterinary Dermatology|December 9, 2004
A retrospective study comparing the histopathological features and response to treatment in two canine nasal dermatoses, DLE and MCPS P Wiemelt, M H Goldschmidt, J S Greek, et al.
The Cochrane Database of Systematic Reviews|July 26, 2002
Bisphosphonates in multiple myelomaB Djulbegovic, K Wheatley, J Ross, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 11, 2001
Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasoneG Egerer, U Hegenbart, H Salwender, et al.
Veterinary Dermatology|September 6, 2019
Discriminatory features of acute eosinophilic dermatitis with oedema (Wells-like syndrome) and sterile neutrophilic dermatosis (Sweet's-like syndrome) in dogsCharles W Bradley, Christine L Cain, Talia S Wong, et al.
Therapeutic Advances in Medical Oncology|June 26, 2023
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)Ran Jin, Adesuwa S Ogbomo, Neil A Accortt, et al.
Bone Marrow Transplantation|November 18, 2000
Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myelomaF W Cremer, E Ehrbrecht, K Kiel, et al.
Bone Marrow Transplantation|December 1, 1993
Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphomaR Haas, R Ehrhardt, B Witt, et al.
Leukemia|September 17, 2010
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activationA C Sprynski, D Hose, A Kassambara, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 1, 1995
[Sequential high-dose therapy in patients with low-malignity non-Hodgkin's lymphoma]R Haas, M Moos, A Karcher, et al.
Pageof 48